This purpose of this resource grant is to function as a core to maintain and create dogs with hemophilia A and B and von Willebrand disease (vWD) for collaborations with other investigators. In the first 3 years of funding, collaborations with at least 12 teams of investigators have been reported in 12 manuscripts. The research is funded on 18 separate research grants. Our objectives in this Resource Grant are: 1) To maintain a breeding colony of well-characterized dogs with genetically-determined bleeding disorders at the Francis Owen Blood Research Laboratory (FOBRL), University of North Carolina, Chapel Hill; 2) To produce purpose-bred research animals with these bleeding disorders; and 3) To provide specialized support services for research projects using these dogs including canine blood banking and coagulation analyses. These dogs modeling human hemophilia A, hemophilia B, and vWD were identified by Dr. Kenneth M. Brinkhous and have been maintained for >50 years in Chapel Hill largely through NIH support. A highly trained staff at the FOBRL has several years of experience in maintaining these special dogs with a dedicated canine blood bank, developing canine coagulation assays, conducting investigations, and collaborating successfully with investigators worldwide. Research using the FOBRL dogs has led to discoveries that have revolutionized the treatment, of inherited and acquired bleeding and thrombotic disorders. Many therapeutic agents were developed and tested in these dogs and successfully translated into clinical therapeutics. Current research with these dogs addresses several unmet national needs including developing new treatments for bleeding, and determining the acute and chronic sequelae of gene therapy on genetic diseases. These dogs constitute an important national resource and are recommended by many investigators and advisory boards as essential for pre-clinical testing of new treatments for the hemophilias, vWD, and hemorrhage. The use of these hemophilic dogs has more than doubled during the past two decades. This grant is the only support for maintenance of this colony. Without this grant, new research using these valuable bleeder dogs would be very difficult and expensive to initiate. The survival of the FOBRL colony would be jeopardized. The cost of establishing a colony at each investigator's institution is prohibitive. The primary benefit of this grant will be to maintain breeding stock for producing affordable, purpose-bred research animals in a cost-effective manner for the research community. This Resource Grant is essential to ensure the survival of the colony in an established, successful environment.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Resource-Related Research Projects (R24)
Project #
5R24HL063098-06
Application #
6775553
Study Section
Special Emphasis Panel (ZHL1-CSR-D (F1))
Program Officer
Link, Rebecca P
Project Start
1999-07-01
Project End
2008-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
6
Fiscal Year
2004
Total Cost
$655,869
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
French, Robert A; Samelson-Jones, Benjamin J; Niemeyer, Glenn P et al. (2018) Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model. Blood Adv 2:505-508
Herzog, Roland W; Nichols, Timothy C; Su, Jin et al. (2017) Oral Tolerance Induction in Hemophilia B Dogs Fed with Transplastomic Lettuce. Mol Ther 25:512-522
Markusic, David M; Nichols, Timothy C; Merricks, Elizabeth P et al. (2017) Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. J Transl Med 15:94
Nichols, T C; Hough, C; Agersø, H et al. (2016) Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies. J Thromb Haemost 14:894-905
Shetty, Krithika A; Merricks, Elizabeth P; Raymer, Robin et al. (2016) Soy Phosphatidylinositol-Containing Lipid Nanoparticle Prolongs the Plasma Survival and Hemostatic Efficacy of B-domain-Deleted Recombinant Canine Factor VIII in Hemophilia A Dogs. J Pharm Sci 105:2459-64
Siner, Joshua I; Samelson-Jones, Benjamin J; Crudele, Julie M et al. (2016) Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models. JCI Insight 1:e89371
Geist, Rebecca E; DuBois, Chase H; Nichols, Timothy C et al. (2016) Experimental Validation of ARFI Surveillance of Subcutaneous Hemorrhage (ASSH) Using Calibrated Infusions in a Tissue-Mimicking Model and Dogs. Ultrason Imaging 38:346-58
Lozier, Jay N; Kloos, Mark T; Merricks, Elizabeth P et al. (2016) Severe Hemophilia A in a Male Old English Sheep Dog with a C?T Transition that Created a Premature Stop Codon in Factor VIII. Comp Med 66:405-411
Marcos-Contreras, Oscar A; Smith, Shannon M; Bellinger, Dwight A et al. (2016) Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII. Blood 127:565-71
Sauna, Zuben E; Lozier, Jay N; Kasper, Carol K et al. (2015) The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics. Blood 125:223-8

Showing the most recent 10 out of 62 publications